In brief
For SaMD, the tooling choice often collapses into two families: a native ALM/eQMS platform you migrate into, or a compliance layer on top of the development flow and QMS you already run. The real pain is rarely “missing features”. It is document rework, lost sync between Jira, Git and the QMS, and the risk of gaps before an audit.
Criteria below (ALM, QMS, SaMD/AI fit, EU vs FDA, implementation) to situate Qapsule + eQMS in your tools against Ketryx, MatrixReq and FormWork. Judgments draw on public positioning and field experience (August 2026). They do not replace a demo.
Qapsule positioning
Qapsule is QARA PULSE's continuous compliance platform. It orchestrates evidence and traceability around tools you already use, without imposing an ALM/eQMS suite. The common field pair: QARA PULSE experts (strategy, CE marking, eQMS) plus a system that stays after the engagement.
On your stack
Connects to Jira, Git, Notion, Atlassian, Drive / SharePoint and neighbouring tools. Goal: one source of truth, no duplicate data entry.
eQMS in your tools
CAPA, training and doc control deployed in the client stack via the QARA PULSE service, then orchestrated continuously by Qapsule.
EU / France anchor
Frame: ISO 13485, IEC 62304, ISO 14971, MDR/IVDR. France hosting (OVHcloud). EU-first market priority.
Comparison table
Key: Yes Partial No . Category-level judgments from public positioning (August 2026). Always validate in a demo.
| Criterion | Ketryx | Matrix Req | FormWork | Qapsule |
|---|---|---|---|---|
| Product logic | Compliance / ALM layer on DevTools | Native ALM/PLM + eQMS suite | eQMS + design controls / techdoc | Continuous compliance layer on stack + eQMS |
| Native requirements & design control | Partial often via DevTools | Yes core product | Yes core product | Partial orchestrates; does not replace ALM |
| Native eQMS (CAPA, training, doc control…) | Partial enforcement in the Dev flow | Yes native suite | Yes native suite | Yes* via eQMS in your tools |
| Layer on Jira / Git / product tools | Yes core product | Partial integrations available | No no DevTools integration | Yes |
| No forced migration into an ALM/eQMS suite | Partial depends on DevOps stack | No often aims at consolidation | No consolidation into FormWork | Yes |
| Traceability & audit-ready evidence | Yes | Yes | Yes | Yes |
| ISO 13485 · IEC 62304 · MDR / IVDR frame | Yes | Yes | Yes | Yes |
| FDA / 21 CFR Part 11 orientation | Yes strong positioning | Yes publicly stated | Yes Part 11 e-signatures | Partial EU-first |
| SaMD / software & medical AI fit | Yes | Yes also hardware / combination | Yes also hardware | Yes software / health AI focus |
| France / EU hosting posture | Partial confirm in contract | Partial confirm in contract | Yes France / Germany | Yes OVHcloud FR |
| Regulatory expert accompaniment tied to the product | Partial CS / product | Partial CS / migration | Partial templates / audit support | Yes QARA PULSE firm |
| Public pricing | No quote / demo | No quote / demo | Yes published on the site | No scoped to context |
* Yes* for Qapsule: the eQMS need (CAPA, training, doc control…) is covered with QARA PULSE's eQMS in your tools service, deployed in the client stack, rather than via a native eQMS suite. Qapsule then orchestrates continuous evidence and traceability.
Qapsule's targeted gains
On the product page, targeted gains are stated as: update evidence up to ×4 faster, centralise 100% of evidence in a traceable way, and aim for 0 duplicate data entry. These are design targets, not a contractual guarantee: outcomes depend on stack, document discipline and initial scoping. If the pain is document rework and lost sync, an orchestration layer often costs less (and less risk before CE) than full ALM/eQMS consolidation.
Action plan
- SaMD / health AI team, especially EU / France, with a CE or notified-body audit timeline.
- Jira, Git and (often) an eQMS or document sprawl already exist; forced migration refused.
- QMS to structure where people already work (CAPA, training, doc control) via eQMS in your tools.
- Continuous audit-ready MDR/IVDR evidence, not only a static requirements system of record.
- A system that stays after the engagement, paired with experts through to the notified body.
It is not the right pick if you want an all-in-one ALM/eQMS that replaces the stack. In that case a native suite remains a separate path.
Conclusion
If your shortlist starts from the assumption that you need a native suite, add Qapsule to challenge that reflex. Often the better fit is to keep what the team already uses, and industrialise compliance around it, with eQMS in your tools and support through to the notified body.
FAQ
Do you need to migrate to an ALM / eQMS suite for SaMD?
Not necessarily. Many SaMD teams already run Jira, Git and a QMS. Migrating to a native suite costs time, adoption and audit risk. Qapsule industrialises evidence and traceability on the stack you already have; the eQMS in your tools service structures CAPA, training and doc control where people already work. A single ALM suite only makes sense if you truly lack a system of record and accept consolidation.
Does Qapsule replace an eQMS?
No. Qapsule orchestrates continuous compliance (evidence, traceability, product / quality sync). The eQMS need is covered with QARA PULSE's eQMS in your tools deployment, in the client stack. The pair fits when you want an operational QMS without an imposed suite, then audit-ready evidence on an ongoing basis.
How does Qapsule work with Jira, Git and an existing eQMS?
Qapsule connects to tools you already use (Jira, Git, Notion, Atlassian, Drive / SharePoint, and similar) and centralises evidence in a traceable way, without duplicate data entry. Published targets are updating evidence up to ×4 faster, centralising 100% of evidence in Qapsule, and aiming for 0 duplicate entry. Outcomes depend on stack, document discipline and initial scoping. See the Qapsule page.
Is Qapsule a fit when the priority market is the EU (MDR / IVDR)?
Yes, that is the most common use case. Qapsule and QARA PULSE are anchored in ISO 13485, IEC 62304, ISO 14971 and MDR/IVDR, with France hosting (OVHcloud) and accompaniment through to the notified body. An FDA / 21 CFR Part 11 posture can be scoped under a custom quote, depending on project scope. To situate this criterion against other market references, see the comparison table above.
How do you frame the tooling choice in 30 minutes with QARA PULSE?
Four points are enough: current stack (Jira, Git, eQMS), priority market (EU, FDA, both), need for a native eQMS versus eQMS in your tools, and CE / audit timeline. Contact us or book a slot: a call often clarifies whether Qapsule + eQMS in your tools + experts is the fit, or whether suite consolidation is truly required.
Category analysis as of August 2026, based on public positioning and QARA PULSE field experience. Not an exhaustive feature benchmark, and not a claim about unpublished roadmaps or certifications. Always verify capabilities, hosting and contract terms with each vendor.